Your browser doesn't support javascript.
loading
Disposable amperometric immunosensor with a dual monomers-based bioconjugate for granzyme B detection in blood and cancer progress monitoring of patients.
Saputra, Heru Agung; Chung, Jae Heun; Yoon, Seong Hoon; Seo, Kyeong-Deok; Park, Deog-Su; Shim, Yoon-Bo.
Afiliación
  • Saputra HA; Institute of BioPhysio Sensor Technology (IBST) and Department of Chemistry, Pusan National University, Busan, 46241, Republic of Korea.
  • Chung JH; Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan-si, 626-770, Republic of Korea.
  • Yoon SH; Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan-si, 626-770, Republic of Korea.
  • Seo KD; Institute of BioPhysio Sensor Technology (IBST) and Department of Chemistry, Pusan National University, Busan, 46241, Republic of Korea.
  • Park DS; Institute of BioPhysio Sensor Technology (IBST) and Department of Chemistry, Pusan National University, Busan, 46241, Republic of Korea.
  • Shim YB; Institute of BioPhysio Sensor Technology (IBST) and Department of Chemistry, Pusan National University, Busan, 46241, Republic of Korea. Electronic address: ybshim@pusan.ac.kr.
Biosens Bioelectron ; 198: 113846, 2022 Feb 15.
Article en En | MEDLINE | ID: mdl-34871833
A disposable amperometric biosensor with a dual monomers-based bioconjugate was developed for granzyme B (GzmB) detection and for monitoring of the cancer progression of patients before and after immunotherapy. The biosensor was fabricated by immobilizing a GzmB monoclonal antibody (Ab1) on a poly3'-(2-aminopyrimidyl)-2,2':5',2''-terthiophene/gold nanoparticle (pPATT/AuNP) layer. The bioconjugate nanoparticles were synthesized through self-assembly of a monomer mixture of 2,2:5,2-terthiophene-3-(p-benzoic acid) (TBA) and PATT onto AuNPs, followed by chemical binding of brilliant cresyl blue (BCB) on TBA and GzmB polyclonal antibody (Ab2) on the PATT layer. Each sensing layer was investigated by surface analysis and electrochemical experiments. The sensor performance was assessed with selectivity, stability, reproducibility, detection limit, and real sample analysis. Under the optimized conditions, the dynamic range of GzmB was in two slopes from 3.0 to 50.0 pg/ml and from 50.0 to 1000.0 pg/ml with a detection limit of 1.75 ± 0.14 pg/ml (RSD ≤5.2%). GzmB monitoring was performed for the patient's serum samples, where a low level of GzmB was observed for lung cancer patients before immunotherapy (10.51 ± 0.99 pg/ml, RSD ≤6.2%), and the level was increased after therapy (17.19 ± 2.22 pg/ml, RSD ≤2.6%). Moreover, a significantly higher level was present in healthy persons (34.40 ± 3.92 pg/ml, RSD ≤1.4%). The cancer progression of patients before and after therapy was evaluated by monitoring GzmB levels in human serum using the proposed sensor.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Técnicas Biosensibles / Nanopartículas del Metal / Neoplasias Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Biosens Bioelectron Asunto de la revista: BIOTECNOLOGIA Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Técnicas Biosensibles / Nanopartículas del Metal / Neoplasias Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Biosens Bioelectron Asunto de la revista: BIOTECNOLOGIA Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido